血浆中转化生长因子β1水平升高与转移性乳腺癌患者生存率降低相关。

Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients.

作者信息

Ivanović Vesna, Demajo Miroslav, Krtolica Koviljka, Krajnović Milena, Konstantinović Miroslav, Baltić Vladimir, Prtenjak Gordana, Stojiljković Bratislav, Breberina Milan, Nesković-Konstantinović Zora, Nikolić-Vukosavljević Dragica, Dimitrijević Bogomir

出版信息

Clin Chim Acta. 2006 Sep;371(1-2):191-3. doi: 10.1016/j.cca.2006.02.027. Epub 2006 Feb 28.

DOI:10.1016/j.cca.2006.02.027

PMID:16650397

Abstract

BACKGROUND

The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients.

METHODS

Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the TbetaRII receptor-based Quantikine TGF-beta(1) ELISA kit.

RESULTS

The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n=37; p>0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p<0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) (>3.00 ng/ml; n=10), was 10%. This was significantly decreased (p<0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGFbeta(1) values close to HD (<3.00 ng/ml, n=19).

CONCLUSION

We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis.

摘要

背景

研究循环中的转化生长因子β1（TGF-β1）在乳腺癌（BC）预后中的作用，旨在确定依赖TGF-β1的高风险和低风险患者亚组。

方法

采用基于TbetaRII受体的Quantikine TGF-β1 ELISA试剂盒，对53例各临床分期的BC患者和37名健康供体（HD）的血浆TGF-β1进行分析。

结果

I/II期疾病患者的血浆TGF-β1水平（中位数：0.94 ng/ml；n = 10）与HD相近（中位数：1.30 ng/ml；n = 37；p>0.1）。相比之下，III/IV期疾病患者（中位数：2.34 ng/ml；n = 43）的TGF-β1水平相对于HD显著升高（p<0.001）。进一步分析表明，TGF-β1升高主要归因于IV期转移性疾病患者（第三四分位数=4.23 ng/ml），而非III/IV期组（第三四分位数=3.58 ng/ml）。以血浆TGF-β1浓度3.00 ng/ml为临界值，形成了两个患者亚组。血浆TGF-β1升高（>3.00 ng/ml；n = 10）的第一亚组患者的总体2年生存率为10%。与血浆TGF-β1值接近HD（<3.00 ng/ml，n = 19）的第二亚组患者52%的生存率相比，该生存率显著降低（p<0.05）。

结论

我们进行了一项初步研究，以确定转移性乳腺癌患者的总生存率与血液中TGF-β1浓度之间的关系。与血浆TGF-β1水平接近正常的患者相比，血浆TGF-β1水平升高的患者生存率显著降低。我们认为，血浆TGF-β1浓度可能是一种新的肿瘤标志物，与转移性BC细胞的存在有关，可用于筛选预后不良的转移性BC患者。